Payment overview · 2025
General Payments
$582.45
31 reported records · 13 companies
Healthcare provider profile · identity verified
Michael D Brown, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEWISBURG, PA · NPI 1386614063
Verified facts
What the public records show
CMS Open Payments records show Michael D Brown, M.D. received $582.45 in general payments during 2025 across 31 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.07 | 15.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.03 | 14.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.02 | 14.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.44 | 11.2% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $43.40 | 7.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.03 | 6.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.87 | 6.3% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $36.02 | 6.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.31 | 5.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.86 | 4.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.83 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.32 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.25 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $582.45 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.07 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.03 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $83.02 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.44 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.31 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 124 |
| Lisinopril | Lisinopril | 317 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 77 |
| Omeprazole | Omeprazole | 232 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 73 |
| Eliquis | Apixaban | 212 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 60 |
| Losartan Potassium | Losartan Potassium | 181 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 56 |
| Metformin Hcl | Metformin Hcl | 173 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 59 |
| Jardiance | Empagliflozin | 138 | 37 |
| Simvastatin | Simvastatin | 136 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 40 |
| Gabapentin | Gabapentin | 113 | 34 |
| Furosemide | Furosemide | 110 | 28 |
| Lorazepam | Lorazepam | 106 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 30 |
| Glimepiride | Glimepiride | 101 | 32 |
| Metformin Hcl Er | Metformin Hcl | 99 | 33 |
| Tramadol Hcl | Tramadol Hcl | 98 | 22 |
| Ozempic | Semaglutide | 96 | 15 |
| Atenolol | Atenolol | 94 | 26 |
| Potassium Chloride | Potassium Chloride | 92 | 21 |
| Clonazepam | Clonazepam | 87 | 16 |
| Amoxicillin | Amoxicillin | 82 | 60 |
| Alprazolam | Alprazolam | 80 | 16 |
| Sertraline Hcl | Sertraline Hcl | 80 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Prednisone | Prednisone | 70 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 13 |
| Trazodone Hcl | Trazodone Hcl | 62 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 23 |
| Allopurinol | Allopurinol | 60 | 24 |
| Meloxicam | Meloxicam | 58 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 33 |
| Warfarin Sodium | Warfarin Sodium | 53 | 13 |
| Cephalexin | Cephalexin | 52 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 23 |
| Carvedilol | Carvedilol | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 12 |
| Fentanyl | Fentanyl | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 14 |
| Methylprednisolone | Methylprednisolone | 28 | 23 |
| Torsemide | Torsemide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 11 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $582.45 · 31 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, FUROSCIX, GARDASIL 9, JARDIANCE, Korlym, M-M-R II, MOUNJARO, PREVNAR 20, QULIPTA, ROTATEQ, UBRELVY, VAQTA, VAXELIS, WAKIX, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error